ARS Pharmaceuticals, Inc. (SPRY)
NASDAQ: SPRY · Real-Time Price · USD
3.730
-0.190 (-4.85%)
Oct 27, 2026, 4:00 PM EDT - Market closed
ARS Pharmaceuticals Stock Forecast
SPRY's stock price has decreased by -59.06% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
According to 4 analysts polled by S&P Global, ARS Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $24.33. The average 1-year stock price forecast is 552.28% higher than the current stock price, while the lowest is $15 (+302.14%) and the highest is $30 (+704.29%).
Price Target: $24.33 (+552.28%)
Analyst Consensus: Strong Buy
Price Target
Chart* Price targets were last updated on Sep 8, 2026.
Analyst Ratings
The average analyst rating for ARS Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 4 | 4 | 4 | 4 | 4 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Leerink Partners | Leerink Partners | Buy Maintains $18 → $15 | Buy | Maintains | $18 → $15 | +302.14% | Sep 8, 2026 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $30 | Buy | Reiterates | $30 | +704.29% | Aug 14, 2026 |
| William Blair | William Blair | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Aug 14, 2026 |
Financial Forecast
Revenue This Year
128.58M
from 84.28M
Increased by 52.57%
Revenue Next Year
187.11M
from 128.58M
Increased by 45.52%
EPS This Year
-1.88
from -1.74
EPS Next Year
-0.90
from -1.88
EPS and Forward PE are based on non-GAAP adjusted numbers.